Latest Headlines

31. StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide 6/24/2026

    StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation.

32. Tecan Accelerates Data-Driven Lab Journey With Agentic AI Developments Powered By NVIDIA 6/24/2026

    Tecan, a global provider of laboratory automation and solutions, today announced the integration of Agentic AI capabilities into its lab analytics platform Introspect, leveraging NVIDIA BioNeMo Agent Toolkit.

33. Versant Diagnostics Expands Collaboration With Leica Biosystems As PRW Laboratories Becomes First To Deploy Aperio GT Elite Solution 6/24/2026

    Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Versant Diagnostics, an independent physician services company actively engaged in next-generation digital pathology, announce an expanded collaboration to advance digital pathology adoption.

34. Legacy Receives New York State CLEP Approval For Two Laboratory-Developed Tests: Semen Analysis And DNA Fragmentation 6/24/2026

    Legacy, a leading male fertility testing and sperm preservation company, today announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP), administered by the Wadsworth Center, has validated and approved two of its laboratory-developed tests: semen analysis and sperm DNA fragmentation analysis.

35. ALZpath Signs Global Licensing Agreement With Abbott To Advance Blood-Based Alzheimer's Disease Testing 6/24/2026

    ALZpath Inc., the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease.

36. VERAXA Biotech Expands R&D Hub In Heidelberg As Innovative BiTAC™-TCE And ADC Programs Advance Towards Clinical Development 6/24/2026

    VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory space at its existing R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.

37. Quest Diagnostics Receives New York State Approval For Haystack MRD®, Broadening Patient Access To ctDNA Minimal Residual Disease Testing 6/24/2026

    Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.

38. New Labcorp Studies Show Promise Of Blood-Based Tests To Predict Liver Disease Risk And Progression 6/23/2026

    Labcorp, a global leader of innovative and comprehensive laboratory services, today announced findings from two peer-reviewed studies demonstrating the potential of blood-based tools to improve risk assessment for metabolic dysfunction-associated steatotic liver disease (MASLD), the most common chronic liver disease in the United States, and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), which can involve significant liver scarring due to fat in the liver.

39. UF Researchers Develop Rapid Urine Diagnostic Test For Prostate Cancer 6/23/2026

    Accurately diagnosing prostate cancer is a challenge. Current screening methods using blood tests sometimes show abnormal results even when a man does not have cancer, or normal results when he does.

40. Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development And AI-Enabled Research At BIO International 2026 6/22/2026

    Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster.